SCHEMBL26210846

SCHEMBL26210846

CN(C)CCNC(=O)c1cccc(O)c1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AOX1 Q06278 1/20 0.56
ALDH1A1 P00352 3/20 0.56
KDM4E B2RXH2 2/20 0.56
ALOX5 P09917 1/20 0.53
PKM P14618 1/20 0.53
MAPK1 P28482 1/20 0.53
EGLN2 Q96KS0 1/20 0.53
LMNA P02545 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.51
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
HTR2C P28335 1/20 0.51
FYN P06241 1/20 0.51
NAMPT P43490 1/20 0.50
USP2 O75604 1/20 0.50
MRGPRX4 Q96LA9 1/20 0.50
AKR1C3 P42330 1/20 0.49
MAP4K4 O95819 1/20 0.49
TP53 P04637 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23484191 0.85 KDM4E (0.69) ALDH1A1KDM4EEGLN2LMNASMN1; SMN2
SCHEMBL26210939 0.84 SMN1; SMN2 (0.55) ALDH1A1PKMMAPK1LMNASMN1; SMN2
SCHEMBL11996634 0.84 NPC1 (0.62) ALDH1A1PKMMAPK1LMNASMN1; SMN2
SCHEMBL3650968 0.83 FYN (0.59) ALDH1A1PKMMAPK1LMNASMN1; SMN2
SCHEMBL13950380 0.83 TP53BP1 (0.60) ALDH1A1KDM4EPKMMAPK1LMNA
SCHEMBL2747362 0.83 MAP4K4 (0.54) ALDH1A1KDM4EPKMMAPK1LMNA
SCHEMBL24333218 0.83 ALDH1A1 (0.52) ALDH1A1KDM4EPKMMAPK1LMNA
SCHEMBL4661410 0.83 PKM (0.61) ALDH1A1KDM4EPKMMAPK1LMNA
SCHEMBL30222110 0.83 PKM (0.61) ALDH1A1KDM4EPKMMAPK1LMNA
SCHEMBL27000117 0.82 SMN1; SMN2 (0.47) AOX1ALDH1A1KDM4EEGLN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11873291-B2 Quinoline cGAS antagonist compounds IMMUNESENSOR THERAPEUTICS, INC. (US) 2024-01-16 US disclosed
US-20230357158-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2023-11-09 US disclosed
WO-2023168367-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS IMMUNESENSOR THERAPEUTICS, INC. (US) 2023-09-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11873291-B2 Quinoline cGAS antagonist compounds CGAS, GLS2, GLS AOX1 2790/4885ALDH1A1 4236/4885KDM4E 4338/4885
US-20230357158-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS CGAS, GLS2, GLS AOX1 2790/4885ALDH1A1 4236/4885KDM4E 4338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.